In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, discusses the key data and nursing considerations for integrating novel classes of agents into the treatment plan for R/R MM, with a focus on combinations with selinexor, venetoclax and melphalan flufenamide.
In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venetoclax, and melphalan flufenamide—into clinical practice for patients with multiple myeloma after multiple relapses. Check back to hear part 2 of this series with a discussion on BCMA-targeted therapy by Donna Catamero, ANP-BC, OCN, CCRC, Associate Director of Myeloma Translational Research at the Mount Sinai Health System.
Presenter:
Tiffany Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas
CE/AAPA credit available by visiting the online program: https://bit.ly/3ee9Ivs
Link to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs